Literature DB >> 29279507

Paget's Disease of Bone Presenting with Peripheral Neuropathy.

Moriharu Misaki1, Osamu Hasegawa1, Toshiaki Takeuchi1.   

Abstract

Entities:  

Keywords:  Paget's disease of bone; risedronate; unilateral lumbar and sacral root involvement

Year:  2017        PMID: 29279507      PMCID: PMC5938515          DOI: 10.2169/internalmedicine.9757-17

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


× No keyword cloud information.
An 81-year-old hypertensive man presented with a high serum alkaline phosphatase (ALP) levels of 1,042 IU/L (normal 110-340) without subjective symptoms. His left knee and ankle jerks were abolished, without motor weakness. A decreased light touch and pinprick sensation in his left L4-S2 dermatome was noticed, and his vibration sense was impaired in the left leg. His index of bone turnover was markedly elevated with a urinary NTx of 255 nmolBCE/mmolCr (13.0-66.2). Radiography showed an increased density, cortical sclerosis and tubercular coarsening in the ileum and sacrum (Picture 1). Bone scintigraphy showed a markedly increased uptake in the involved bones (Picture 2, arrow), indicated Paget's disease of bone. Oral risedronate at 17.5 mg daily (1) was started. Forty days after starting treatment, his serum ALP and urinary NTx levels decreased to 478 IU/L and 20.2 nmolBCE/mmolCr, respectively. He showed improvement of the sensory disturbances and tendon jerks. Some non-compressive mechanism at the left sacral canal might have provoked peripheral neuropathy (2).
Picture 1.
Picture 2.
The authors state that they have no Conflict of Interest (COI).
  2 in total

Review 1.  Neurologic complications of Paget disease of bone.

Authors:  Daniel J Rubin; Robert M Levin
Journal:  Endocr Pract       Date:  2009-03       Impact factor: 3.443

2.  Clinical efficacy of oral risedronate therapy in Japanese patients with Paget's disease of bone.

Authors:  Masaya Ohara; Yasuo Imanishi; Yuki Nagata; Akira Ishii; Ikue Kobayashi; Katsuhito Mori; Manabu Ito; Takami Miki; Yoshiki Nishizawa; Masaaki Inaba
Journal:  J Bone Miner Metab       Date:  2014-10-16       Impact factor: 2.626

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.